mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor α serine 167 phosphorylation | Zendy

Yamnik Rachel L. | Zendy; Holz Marina K. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor α serine 167 phosphorylation

Author(s) -

Yamnik Rachel L.,

Holz Marina K.

Publication year - 2010

Publication title -

febs letters

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.593

H-Index - 257

eISSN - 1873-3468

pISSN - 0014-5793

DOI - 10.1016/j.febslet.2009.11.041

Subject(s) - phosphorylation , p70 s6 kinase 1 , estrogen receptor , pi3k/akt/mtor pathway , cancer research , mapk/erk pathway , signal transduction , estrogen , serine , breast cancer , estrogen receptor alpha , microbiology and biotechnology , biology , chemistry , cancer , endocrinology , genetics

Resistance to anti‐estrogen therapy is a major clinical concern in treatment of breast cancer. Estrogen‐independent phosphorylation of estrogen receptor α, specifically on Ser167, is one of the contributing causes to development of resistance, and a prognostic marker for the disease. Here, we dissect the signaling pathways responsible for Ser167 phosphorylation. We report that the mTOR/S6K1 and MAPK/RSK contribute non‐overlapping inputs into ERα activation via Ser167 phosphorylation. This cooperation may be targeted in breast cancer treatment by a combination of mTOR and MAPK inhibitors.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research